Highest-materiality recent filing
GT Biopharma enters agreement with Univ. of Minnesota for Phase 1a/1b trial of GTB-5550
Agreement for IND 169118 GTB-5550 (camB7-H3 TriKE) in advanced solid tumors that failed prior therapy.
GT Biopharma restates Q2/Q3 2025 financials; Greenshoe Rights liability misclassified
Audit committee concluded non-reliance on Q2 and Q3 2025 Form 10-Q after finding Greenshoe Rights should have been liability under ASC 480.
GT Biopharma receives Nasdaq delisting notice for low bid price
Nasdaq notified GT Biopharma on Nov 20, 2025 that stock closed below $1 for 30 consecutive days, violating Minimum Bid Price Requirement.
GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026
Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.
GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement
All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.
GT Biopharma series L preferred holders waive redemption rights permanently
Holders of Series L 10% Convertible Preferred Stock waived redemption rights under Section 10 of the Certificate of Designations.
GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025
CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.
GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment
All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.
GT Biopharma appoints new director, amends equity facility to raise up to $20M
Andrew Ritter resigned from board effective June 9, 2025.
GT Biopharma expands private placement to $5.95M, adds new investor Marzilli
Increased Series L preferred offering to 6,612 shares ($5.95M) from 6,056 shares ($5.45M) via First Amendment on May 21, 2025.
On June 10, 2025, the Board appointed David C. Mun-Gavin as a non-employee director of the Board.
On June 9, 2025, Andrew Ritter resigned as a member of the board of directors (the “Board”) of the Company and all committees thereof.
Max materiality 0.90 · Median 0.55 · Most common event other_material